Eli Lilly has announced plans to conduct a clinical trial of rheumatoid arthritis drug baricitinib (Olumiant) for the treatment of patients with Covid-19.
The company signed an agreement with the National Institutes of Health (NIH)’s National Institute of Allergy and Infectious Diseases (NIAID) to add a baricitinib arm in NIAID’s Adaptive COVID-19 Treatment Trial.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
